He died of an overdose—after $110,000 in addiction treatment

In August 2017, Sean Blake died of an overdose, after nearly a decade cycling in and out of addiction treatment programs that cost his family $110,000—a story that highlights the flaws in the U.S. addiction treatment system, German Lopez reports for Vox.

Read More
Advisory Board Insight

Can junk food really make you go blind? It’s complicated.

A case report in the Annals of Internal Medicine highlights a severe case of avoidant-restrictive food intake disorder that doctors believe led a 17-year-old boy, who ate only a limited array of "junk food," to go blind—but one expert is questioning whether the boy's diet was the only factor at play.

At least 3,500 donated kidneys are thrown away every year in the US, study finds

There are 93,000 people in the United States waiting for a kidney transplant, and kidney disease kills about 5,000 U.S. residents on the kidney waiting list annually—yet a study published last week in JAMA Internal Medicine estimated the United States throws away at least 3,500 donated kidneys every year.

Twitter roundup: The 10 tweets that caught our eye this week

Aledade's new move in California, why you should be suspicious of "miracle meat," and more health care tweets that caught our eye this week.

Around the nation: NYC health officials declare measles outbreak over

The announcement marks the end of the largest measles outbreak in New York City in three decades, in today's bite-sized hospital and health industry news from New York, Ohio, and Texas.

Did California's physician payment rate setting law work? Experts are split.

A California law touted as a national model for addressing so-called "surprise bills" has led to fewer surprise bills for patients and lower payment rates for in-network and out-of-network physicians—but it may be driving physician group consolidation, according to recent research.

Hospitals are avoiding admitting Medicare patients to dodge financial penalties, study suggests

A study published recently in BMJ reinforces concerns that hospitals are treating Medicare patients in EDs and observation areas instead of admitting them to the hospital to avoid readmissions penalties.

A controversy erupts: Should we give up hope on biosimilars?

A recent Wall Street Journal opinion piece has spurred debate over whether it's time to abandon biosimilars in the quest for more affordable biologic drugs. Here's what the piece argued, former FDA Commissioner Scott Gottlieb's rebuttal of it, and where Advisory Board experts side.